Xintela AB (OSTO:XINT) Total Equity: kr-17.51 Mil (As of Mar. 2026)


OSTO:XINT Xintela AB OSTO:XINT
8 GF Score
Price kr0.20
! 2 Warning Signs
View Full Analysis

What is Xintela AB Total Equity?

Xintela AB OSTO:XINT +1.49% 8 Total Equity is kr-17.51 Mil as of Mar. 2026. GuruFocus rates OSTO:XINT with a GF Score™ of 8/100. The stock has 2 warning signs investors should review.

Xintela AB's total equity for the quarter that ended in Mar. 2026 was kr-17.51 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Xintela AB Total Equity Historical Data

* Premium members only.

The historical data trend for Xintela AB's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xintela AB Total Equity Chart

Xintela AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.51 5.78 4.38 -5.95 -5.27

Xintela AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -16.65 -18.54 -27.88 -5.27 -17.51
OSTO:XINT
8GF Score
Xintela AB OSTO:XINT
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Xintela AB Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Xintela AB's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=29.025-34.298
=-5.27

Xintela AB's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=14.63-32.14
=-17.51

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of kr-17.51 Mil mean?
Xintela AB (OSTO:XINT) has a Total Equity of kr-17.51 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Xintela AB and its competitors.
Is Xintela AB's Total Equity too high?
Xintela AB's current Total Equity is kr-17.51 Mil. Overall, Xintela AB has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Xintela AB's Total Equity compare to VRTX and REGN?
Xintela AB's Total Equity of kr-17.51 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Xintela AB and its competitors. Xintela AB's current Total Equity is kr-17.51 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xintela AB stock overvalued right now?
Xintela AB (OSTO:XINT) has a current Total Equity of kr-17.51 Mil. The current Total Equity is kr-17.51 Mil. Xintela AB's overall GF Score™ is 8/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Xintela AB (OSTO:XINT), the current Total Equity is kr-17.51 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Xintela AB Business Description

Other Exchanges 1XT:Germany
Address Medicon Village, Lund, SWE, 223 81
Xintela AB is a clinical-stage biopharmaceutical company that develops cutting-edge medical products in stem cell therapy and targeted cancer therapy. Its wholly owned subsidiary, Targinta AB, develops First-in-Class therapeutic antibodies targeting integrin ?10?1. TARG9, an antibody-drug conjugate (ADC), and TARG10, a function-blocking antibody, are in preclinical development for the treatment of aggressive, difficult-to-treat cancers, including triple-negative breast cancer and brain tumor glioblastoma. Xintela has two clinical studies ongoing with the stem cell product XSTEM and EQSTEM.
8GF Score

Get the complete analysis for OSTO:XINT

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.20
Price